MGH | Biomarker Commons

MGH

Third-generation Device Significantly Improves Capture of Circulating Tumor Cells

A new system for isolating rare circulating tumor cells (CTCs) – living solid tumor cells found at low levels in the bloodstream – shows significant improvement over previously developed devices and does not require prior identification of tumor-specific target molecules. Developed at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine and the MGH Cancer Center, the device rapidly delivers a population of unlabeled tumor cells that can be analyzed with both standard clinical diagnostic cytopathology and advanced genetic and molecular technology.


Tags:

Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study

Veridex, LLC (Veridex) recently announced that the first study of the company's next-generation circulating tumor cell (CTC) technology, developed in collaboration with researchers at Massachusetts General Hospital (MGH), has been published in Science Translational Medicine. The collaboration, initially announced in January 2011, has led to the development of a next-generation CTC (or "liquid biopsy") technology that offers enhanced specificity and sensitivity and enables more extensive characterization of captured cells.


Tags:

Premium Subscription Required for Access


Tags:

Premium Subscription Required for Access


Tags:

Premium Subscription Required for Access


Tags:

Premium Subscription Required for Access


Tags: